A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

• ClinicalTrials.gov Identifier: NCT02124564
• Recruitment Status: Completed
• First Posted: April 28, 2014
• Results First Posted: June 28, 2019
• Last Update Posted: October 28, 2019
• Sponsor: UCB Japan Co. Ltd.
• Information provided by (Responsible Party): UCB Pharma ( UCB Japan Co. Ltd. )

Study Description

Brief Summary:

This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200 mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have partial-onset seizures with or without secondary generalization and who are treated with a single Anti-Epileptic Drug (AED) with marketing approval in Japan.

Condition or disease	Intervention/treatment	Phase
Epilepsy; Partial-onset Seizures	Drug: Lacosamide	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 19 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without Secondary Generalization
• Actual Study Start Date: April 2014
• Actual Primary Completion Date: November 21, 2017
• Actual Study Completion Date: November 21, 2017

Arms and Interventions

Arm

Intervention/treatment

Experimental: Lacosamide; Open-label, single-arm

Drug: Lacosamide; Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.; 4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .; The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day.; Other Name: Vimpat

Outcome Measures

Primary Outcome Measures :

1. Number of Subjects With at Least One Incidence of Treatment-Emergent Adverse Events (TEAEs) During the Study [ Time Frame: From the Titration Period (investigational product is taken) to the End of Study Visit (up to 3.5 years) ]
   An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
2. Number of Subjects Who Withdraw Due to Adverse Events (AEs) During the Study [ Time Frame: From the Titration Period (investigational product is taken) to the End of Study Visit (up to 3.5 years) ]
   An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
3. Number of Subjects With at Least One Incidence of Serious Adverse Events (SAEs) During the Study [ Time Frame: From the Titration Period (investigational product is taken) to the End of Study Visit (up to 3.5 years) ]

   A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

   • Results in death
   • Is life-threatening
   • Requires in patient hospitalization or prolongation of existing hospitalization
   • Is a congenital anomaly or birth defect
   • Is as infection that requires treatment parenteral antibiotics
   • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

Secondary Outcome Measures :

1. Number of Subjects Remaining Seizure Free for 6 Consecutive Months During the Monotherapy Period [ Time Frame: From the beginning of the Monotherapy Period to the end of the Follow-Up Period (up to 3.1 years until the time of approval granted) ]

   Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.

   A subject was considered seizure free, if no seizure occurred during the 6 consecutive months in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:

   • A documented seizure during 6 consecutive months of the Evaluation Analysis Period
   • Subject discontinued the study prematurely during the Evaluation Analysis Period
   • Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period
2. Number of Subjects Remaining Seizure Free for 12 Consecutive Months During the Monotherapy Period [ Time Frame: From the beginning of the Monotherapy Period to the end of the Follow-Up Period (up to 3.1 years until the time of approval granted) ]

   Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.

   A subject was considered seizure free, if no seizure occurred during the 12 consecutive months in the Evaluation Period. If one of the following occurred, the subject was not considered seizure free:

   • A documented seizure during 6 consecutive months of the Evaluation Analysis Period
   • Subject discontinued the study prematurely during the Evaluation Analysis Period
   • Missing Seizure Count Case Report Forms (CRFs) prior to completing the Evaluation Analysis Period.

   Subjects who discontinued before the end date of 6 consecutive months were included in this analysis.

3. Percentage of Participants in the Monotherapy Period Without Discontinuation Due to Adverse Events (AE) or Lack of Efficacy (LOE) [ Time Frame: From the beginning of the Monotherapy Period to the end of the Follow-Up Period (up to 3.1 years until the time of approval granted) ]
   For Time to discontinuation (event), Retention rate and 95% CI was calculated using the Kaplan-Meier method. Retention rate is indicated in Percent and 95% confidence intervals (CI) with respect to the Time to discontinuation.
4. Plasma Concentrations of Lacosamide Versus Time Postdose [ Time Frame: From Titration Period up to Week 94 ]
   Dose-normalized lacosamide Plasma Concentration (µg/mL) by Visit and Dose during the Evaluation Period.

Eligibility Criteria

• Ages Eligible for Study: 16 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Subject is male or female and ≥16 years of age
• Subject has a diagnosis of epilepsy, having experienced unprovoked partial-onset seizures (IA, IB, or IC with clear focal origin) that are classifiable according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 1981
• Subject experiences partial-onset seizures despite appropriately chosen and adequately tried treatment with 1 antiepileptic drug (AED)
• Subject has been treated for epilepsy with a stable dose of 1 marketed AED The use of benzodiazepines is permitted as rescue therapy for epilepsy. Benzodiazepines may have been used as needed but not more frequently than once per week.

Exclusion Criteria:

• Subject has a history or presence of seizures of other types than partial onset (IA, IB, or IC with clear focal origin)
• Subject is taking benzodiazepines for a nonepilepsy indication (Exception: Concomitant use of benzodiazepines is allowed if the subject is taking them on a regular basis, has been on a stable dose for at least 1 month prior to Visit 1, and does not require changes in the dosage and administration throughout the study period. However, concomitant use of benzodiazepines on an as needed basis is not permitted.)
• Female subject who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 years postmenopausal or does not practice 1 highly effective method of contraception, unless sexually abstinent, for the duration of the study
• Female subject of childbearing potential taking enzyme-inducing antiepileptic drugs (EI-AEDs: CBZ, phenytoin, barbiturates, primidone, topiramate) who is not surgically sterile, 2 years postmenopausal or does not practice 1 highly effective method of contraception according to the World Health Organization (WHO) recommendation (ie, depot medroxyprogesterone acetate, norethisterone enantate, intrauterine devices, combined injectables, and progestogen implants) with administration of EI-AEDs or does not practice 2 combined methods of contraception (ie, combined hormonal contraception plus barrier method with spermicidal agent), unless sexually abstinent, for the duration of the study
• Subject has sick sinus syndrome without a pacemaker, or a second or third degree atrioventricular (AV) block, or subject has any other clinically relevant electrocardiogram (ECG) abnormalities
• Subject has a history of convulsive status epilepticus within the last 12 months prior to Visit 1

Contacts and Locations

Locations

Japan

5

Asaka, Japan

1

Hamamatsu, Japan

11

Itami, Japan

6

Kagoshima, Japan

7

Kamakura, Japan

10

Nagoya, Japan

12

Saitama, Japan

8

Sapporo, Japan

13

Shinagawa, Japan

4

Shizuoka, Japan

9

Toyonaka, Japan

Sponsors and Collaborators

UCB Japan Co. Ltd.

Investigators

• Study Director: UCB Cares; +1 844 599 2273 (UCB)

  Study Documents (Full-Text)

Documents provided by UCB Pharma ( UCB Japan Co. Ltd. ):

Study Protocol  [PDF] October 9, 2013

Statistical Analysis Plan  [PDF] April 21, 2016

More Information

• Responsible Party: UCB Japan Co. Ltd.
• ClinicalTrials.gov Identifier: NCT02124564
• Other Study ID Numbers: EP0057
• First Posted: April 28, 2014
• Results First Posted: June 28, 2019
• Last Update Posted: October 28, 2019
• Last Verified: October 2019

Keywords provided by UCB Pharma ( UCB Japan Co. Ltd. ):

Lacosamide; Epilepsy; Focal, Partial-Onset Seizures with or without secondary generalization; Monotherapy

Additional relevant MeSH terms:

Epilepsy; Seizures; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Lacosamide; Anticonvulsants; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action